Progress report from the Division of Behavioral Biology, the Johns Hopkins University School of Medicine.
D000818:Animals; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D002077:Butorphanol / Q000008:administration & dosage / Q000494:pharmacology; D003061:Codeine / Q000008:administration & dosage / Q000494:pharmacology; D003216:Conditioning, Operant; D003975:Diazepam / Q000494:pharmacology; D004193:Discrimination Learning / Q000187:drug effects; D006801:Humans; D009020:Morphine / Q000008:administration & dosage / Q000494:pharmacology; D009266:Nalbuphine / Q000008:administration & dosage / Q000494:pharmacology; D009294:Narcotics / Q000008:administration & dosage* / Q000494:pharmacology; D010076:Oxazepam / Q000494:pharmacology; D010423:Pentazocine / Q000008:administration & dosage / Q000494:pharmacology; D011680:Pupil / Q000187:drug effects; D012646:Self Administration
D014151:Anti-Anxiety Agents; D009294:Narcotics; D010076:Oxazepam; D009020:Morphine; D009266:Nalbuphine; D003975:Diazepam; D002077:Butorphanol; D010423:Pentazocine; D003061:Codeine